-
Kaleido Biosciences OTC MARKETS:KLDO Kaleido Biosciences is a clinical-stage healthcare company with a differentiated, chemistry-driven approach to targeting the microbiome to treat disease and improve human health. The Company has built a proprietary product platform to enable the rapid and cost-efficient discovery and development of novel Microbiome Metabolic Therapies (MMT™). MMTs are designed to modulate the metabolic output and profile of the microbiome by driving the function and distribution of the gut's existing microbes. Kaleido is advancing a broad pipeline of MMT candidates with the potential to address a variety of diseases and conditions with significant unmet patient needs.
Location: | Website: kaleido.com | Industry: Medicinal and Botanical Manufacturing | Sector: Manufacturing
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
-16.78M
Cash
38.47M
Avg Qtr Burn
-19.27M
Short % of Float
5.51%
Insider Ownership
0.00%
Institutional Own.
0.03%
Qtr Updated
12/31/21
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
KB195 Details UCD (Urea Cycle Disorders) | Failed Discontinued | |
KB295 Details Inflammatory bowel disease | Failed Discontinued | |
KB109 Details Chronic obstructive pulmonary disease | Failed Discontinued |